Rational design of potent human transthyretin amyloid disease inhibitors

The human amyloid disorders, familial amyloid polyneuropathy, familial amyloid cardiomyopathy and senile systemic amyloidosis, are caused by insoluble transthyretin (TTR) fibrils, which deposit in the peripheral nerves and heart tissue. Several nonsteroidal anti-inflammatory drugs and structurally similar compounds have been found to strongly inhibit the formation of TTR amyloid fibrils in vitro. These include flufenamic acid, diclofenac, flurbiprofen, and resveratrol. Crystal structures of the protein–drug complexes have been determined to allow detailed analyses of the protein–drug interactions that stabilize the native tetrameric conformation of TTR and inhibit the formation of amyloidogenic TTR. Using a structure-based drug design approach ortho-trifluormethylphenyl anthranilic acid and N-(meta-trifluoromethylphenyl) phenoxazine 4,6-dicarboxylic acid have been discovered to be very potent and specific TTR fibril formation inhibitors. This research provides a rationale for a chemotherapeutic approach for the treatment of TTR-associated amyloid diseases.

[1]  J. Folts,et al.  Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. , 1995, Circulation.

[2]  H. Díaz,et al.  A dibenzofuran-based amino acid designed to nucleate antiparallel .beta.-sheet structure: evidence for intramolecular hydrogen-bond formation , 1992 .

[3]  J. Kelly,et al.  The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. , 1998, Current opinion in structural biology.

[4]  P. A. Peterson,et al.  Studies on thyroid hormone-binding proteins. II. Binding of thyroid hormones, retinol-binding protein, and fluorescent probes to prealbumin and effects of thyroxine on prealbumin subunit self association. , 1975, The Journal of biological chemistry.

[5]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[6]  J. Kelly,et al.  Alternative conformations of amyloidogenic proteins govern their behavior. , 1996, Current opinion in structural biology.

[7]  S J Oatley,et al.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. , 1977, Journal of molecular biology.

[8]  Scott A. Peterson,et al.  Discovering transthyretin amyloid fibril inhibitors by limited screening. , 1998, Bioorganic & medicinal chemistry.

[9]  H. Hodkinson,et al.  The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. , 1977, The Quarterly journal of medicine.

[10]  W. Bernini,et al.  Antiplatelet activity of synthetic and natural resveratrol in red wine. , 1995, International journal of tissue reactions.

[11]  Scott A. Peterson,et al.  Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the non-steroidal anti-inflammatory drug, flufenamic acid. , 1999, Bioorganic & medicinal chemistry.

[12]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[13]  D. Craik,et al.  Drug competition for thyroxine binding to transthyretin (prealbumin): comparison with effects on thyroxine-binding globulin. , 1989, The Journal of clinical endocrinology and metabolism.

[14]  J. Buxbaum,et al.  Genetic aspects of amyloidosis. , 1991, Advances in human genetics.

[15]  M. Feldman,et al.  Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. , 1998, The American journal of medicine.

[16]  J. Buxbaum,et al.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. , 1997, The New England journal of medicine.

[17]  A Coda,et al.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.

[18]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1997, Nature.

[19]  H. M. Petrassi,et al.  Structure-Based Design of N-Phenyl Phenoxazine Transthyretin Amyloid Fibril Inhibitors , 2000 .

[20]  J. Kelly,et al.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.

[21]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[22]  J. Kelly,et al.  Synthesis and evaluation of anthranilic acid-based transthyretin amyloid fibril inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[23]  A. Wojtczak,et al.  HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE , 1996 .

[24]  T. Coelho Familial amyloid polyneuropathy: new developments in genetics and treatment , 1996, Current opinion in neurology.

[25]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[26]  Scott A. Peterson,et al.  Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  S V Evans,et al.  SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. , 1993, Journal of molecular graphics.

[28]  S. Nilsson Studies on thyroid hormone-binding proteins , 1973 .

[29]  J. Kelly,et al.  Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. , 1995, Biochemistry.

[30]  C. Blake,et al.  Strjcture of human plasma prealbumin at 2-5 A resolution. A preliminary report on the polypeptide chain conformation, quaternary structure and thyroxine binding. , 1974, Journal of molecular biology.

[31]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[32]  J. Kelly,et al.  Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.

[33]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[34]  M. Maccarrone,et al.  Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. , 1999, European journal of biochemistry.